Apellis Pharmaceuticals Stock Performance
| APLS Stock | USD 22.58 0.47 2.04% |
On a scale of 0 to 100, Apellis Pharmaceuticals holds a performance score of 5. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Apellis Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Apellis Pharmaceuticals is expected to be smaller as well. Please check Apellis Pharmaceuticals' skewness, and the relationship between the total risk alpha and day median price , to make a quick decision on whether Apellis Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Apellis Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak essential indicators, Apellis Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.11 | Five Day Return 1.74 | Year To Date Return (11.72) | Ten Year Return 62.72 | All Time Return 62.72 |
1 | A Look at Apellis Pharmaceuticalss Valuation Following Strong Third Quarter Profit Turnaround - simplywall.st | 11/11/2025 |
2 | Apellis Pharmaceuticals Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval | 12/05/2025 |
3 | Acquisition by Wheeler Craig A of 14684 shares of Apellis Pharmaceuticals at 25.12 subject to Rule 16b-3 | 12/31/2025 |
4 | Assessing Apellis Pharmaceuticals Valuation After 2025 Revenue Update And Pipeline Progress | 01/14/2026 |
5 | Cantor Fitzgerald Cuts Apellis Pharmaceuticals Price Target to 35.00 | 01/16/2026 |
6 | Disposition of 2475 shares by Watson David O. of Apellis Pharmaceuticals at 19.7929 subject to Rule 16b-3 | 01/20/2026 |
7 | Insider Selling Apellis Pharmaceuticals Insider Sells 5,928 Shares of Stock | 01/23/2026 |
8 | Acquisition by Francois Cedric of 195952 shares of Apellis Pharmaceuticals subject to Rule 16b-3 | 01/28/2026 |
9 | Apellis Pharmaceuticals Valuation Check As Shares Trade Around US23 After Mixed Return Performance | 01/30/2026 |
| Begin Period Cash Flow | 352.3 M | |
| Total Cashflows From Investing Activities | -403 K |
Apellis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,995 in Apellis Pharmaceuticals on November 5, 2025 and sell it today you would earn a total of 263.00 from holding Apellis Pharmaceuticals or generate 13.18% return on investment over 90 days. Apellis Pharmaceuticals is currently generating 0.2726% in daily expected returns and assumes 3.6189% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Apellis, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apellis Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Apellis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 22.58 | 90 days | 22.58 | about 52.61 |
Based on a normal probability distribution, the odds of Apellis Pharmaceuticals to move above the current price in 90 days from now is about 52.61 (This Apellis Pharmaceuticals probability density function shows the probability of Apellis Stock to fall within a particular range of prices over 90 days) .
Apellis Pharmaceuticals Price Density |
| Price |
Predictive Modules for Apellis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Apellis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Apellis Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Apellis Pharmaceuticals is not an exception. The market had few large corrections towards the Apellis Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Apellis Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Apellis Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.31 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 2.75 | |
Ir | Information ratio | -0.06 |
Apellis Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Apellis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Apellis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Apellis Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 781.37 M. Net Loss for the year was (197.88 M) with profit before overhead, payroll, taxes, and interest of 605.05 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (87.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Apellis Pharmaceuticals Valuation Check As Shares Trade Around US23 After Mixed Return Performance |
Apellis Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Apellis Stock often depends not only on the future outlook of the current and potential Apellis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apellis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 123.9 M | |
| Cash And Short Term Investments | 416.1 M |
Apellis Pharmaceuticals Fundamentals Growth
Apellis Stock prices reflect investors' perceptions of the future prospects and financial health of Apellis Pharmaceuticals, and Apellis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apellis Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0513 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 2.91 B | ||||
| Shares Outstanding | 126.53 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 7.27 X | ||||
| Price To Sales | 2.84 X | ||||
| Revenue | 781.37 M | ||||
| Gross Profit | 605.05 M | ||||
| EBITDA | (154.53 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 3.17 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Earnings Per Share | 0.36 X | ||||
| Market Capitalization | 2.89 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
About Apellis Pharmaceuticals Performance
Assessing Apellis Pharmaceuticals' fundamental ratios provides investors with valuable insights into Apellis Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Apellis Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 294.10 | 279.40 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (1.00) | (1.05) |
Things to note about Apellis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Apellis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apellis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apellis Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 781.37 M. Net Loss for the year was (197.88 M) with profit before overhead, payroll, taxes, and interest of 605.05 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (87.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Apellis Pharmaceuticals Valuation Check As Shares Trade Around US23 After Mixed Return Performance |
- Analyzing Apellis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apellis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Apellis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apellis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apellis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apellis Pharmaceuticals' stock. These opinions can provide insight into Apellis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.